CARRA
Childhood Arthritis and Rheumatology Research Alliance

Corporate Partner Program

# Advancing Innovation in Pediatric Rheumatology

ACCELERATING PEDIATRIC DRUG DEVELOPMENT AND UNDERSTANDING THE TREATMENT LANDSCAPE OF CHILDREN WITH RHEUMATIC DISEASE



*Fall 2026*

carragroup.org

## OUR MISSION

**To unite the pediatric rheumatology community to drive research and transform the lives of children with rheumatic diseases.**

CARRA

## OUR VISION

**A world where every child with rheumatic disease thrives.**



WHO WE ARE TODAY

# A national network and robust community of more than 800 pediatric rheumatologists, investigators, scientists, fellows-in-training, research coordinators, and patients and families advancing critical research, stakeholder collaboration, real-world data & infrastructure, and innovation in pediatric rheumatology.

**>80%**

of pediatric rheumatologists are CARRA members

**16,000+**

Unique patients enrolled in the CARRA Registry and Biorepository with data collected in JIA, SLE, JDM and associated diseases

**>85%**

of expenses go to programs and services

**50**

active disease-specific and special interest workgroups across 13 scientific committees

CARRA

CORE ORGANIZATIONAL PRIORITIES

# Advancing the future of pediatric rheumatology through three critical initiatives

1

## CARRA REGISTRY: NEXT-GENERATION RESEARCH INFRASTRUCTURE

Modernizing and optimizing the CARRA Registry and Biorepository to accelerate the discovery and equitable delivery of the best and safest treatments for children with rheumatic disease.

2

## ACCELERATING PEDIATRIC DRUG DEVELOPMENT APPROVALS

Partnering with regulators, industry, clinicians, and families to reduce barriers to pediatric clinical trials.

Developing FDA-aligned frameworks, innovative trial designs, and real-world evidence to speed access to new therapies.

3

## TRANSFORMING CARE THROUGH EMERGING THERAPY INNOVATION

Advancing efforts for emerging therapies, including cellular, in pediatric rheumatic diseases.

Building the clinical infrastructure, care models, and collaborative networks needed to bring next-generation treatments to children faster.

CARRA

CURRENT CHALLENGES


# Barriers to pediatric therapy innovation and outcomes for children

Pharmaceutical companies are often hesitant to invest in pediatrics or run clinical trials even when they hold a medicine that could change a child's life. The cost, resources, time, and recruitment challenges involved can be prohibitive for advancing potential therapeutic options.

CARRA is working on solutions. However, we cannot do this important work alone. To ensure that children have access to life-changing medicines, CARRA is advancing strategies and seeking committed partners to help us close the gaps and transform the landscape.

**Reducing the barriers to bring pediatric therapies to market is critical for expanding access for pediatric patients.**

**CARRA is focused on accelerating pediatric drug approvals to support bringing new therapies to market for children with rheumatic diseases.**



CORPORATE PARTNER PROGRAM

# The value of partnership

Investments in the **Corporate Partner Program** enable CARRA to work on critical initiatives that accelerate pediatric drug development in partnership, strengthen the Registry and Biorepository for the entire community, deepen engagement with patients and families, and support the workforce needed to care for future generations.

Corporate partnership fuels modernization, collaboration, and essential field-wide infrastructure to support the resources needed for critical research.

**Commitments made through the Corporate Partner Program empower transformational initiatives that advance pediatric rheumatology toward a world where every child with rheumatic disease can thrive.**

CORPORATE PARTNERSHIP

# Partnering with CARRA



CARRA

ENGAGEMENT STRENGTHENS OUTCOMES

# Partnering with CARRA

1

## Pediatric Drug Development

CARRA sits at the center of the autoimmune and inflammatory ecosystem, which means partners can leverage CARRA to accelerate drug development priorities and regulatory engagement.

Collaborating with CARRA will help make pediatric drug development more efficient, more informed, and ultimately more successful.

2

## Evidence Generation and Lifecycle Management

CARRA is a strategic partner for lifecycle management, providing early scientific insight, real-world evidence, and clinician-driven expertise that strengthen development from early studies through post-marketing commitments.

By connecting pharma with a unified pediatric network and robust longitudinal data, CARRA accelerates evidence generation and enhances therapeutic impact across therapeutic lifespan.

3

## Understand Disease at its Earliest Expression

CARRA gives adult rheumatology teams a direct window into early disease onset of the same diseases they treat, providing scientific insight, real-world evidence, and patient experience that strengthen adult drug strategy across the entire lifecycle and the ability to develop more effective therapies.

CARRA

PARTNERING WITH CARRA


# Accelerating drug development initiative

CARRA is convening a collaborative initiative with the FDA, patient groups, physician specialists, scientists, and other stakeholders to accelerate treatment development and the approval of therapies for children.

Together with our partners, we are creating a comprehensive roadmap to advance solutions to barriers including extrapolation, clinical trial design, and site readiness.

OBJECTIVE

**Reduce the barriers between promising pediatric therapies and the children who need them.**



PARTNERING WITH CARRA

# The home of pediatric rheumatology leaders & experts

CARRA's Scientific Committees and Workgroups bring together experts to advance pediatric rheumatology care, research, disease understanding, and other strategic initiatives across 13 different committees and 50 workgroups. These groups include members investing resources in JIA, JSpA, JDM, SLE, LN, Sjögren's disease, Scleroderma, and other rheumatic diseases.

Truly collaborative and forward-thinking, these groups are the heart of pediatric community engagement and innovation at CARRA.

**Corporate partners can participate in these disease-specific workgroups and committees, putting partners on the front lines with patients, families, and pediatric rheumatologists.**




**13**
scientific committees

**50**
workgroups

CARRA

PARTNERING WITH CARRA

# Our committees and workgroups

**13** committees

**50** workgroups

CARRA's workgroups bring together physicians, researchers, and patients and families to advance pediatric rheumatology initiatives. Committees report to the CARRA Scientific Advisory Committee.

**CARRA Scientific Advisory Committee**

### DISEASE-SPECIFIC RESEARCH COMMITTEES

JIA · JDM · SLE · Rare disease

Workgroups include sJIA, Uveitis, Lupus nephritis, JSpA, Pediatric scleroderma, Therapeutics, CNO/CRMO, and Sjögren's disease.

### TOPIC-BASED COMMITTEES

Consensus Treatment Plan · Data management & analysis · Development & revision · Pain · Implementation science

### TRANSLATIONAL & CROSS-CUTTING RESEARCH

Genomic data management and sharing · Patient/Family Advisory Council · Mental health · Transition · Health equity research

### STAKEHOLDER & ADVISORY COMMITTEES

Early Career · Fellows · DEIA · Research Coordinator Network · Small Centers

PARTNERING WITH CARRA

# Patient & family engagement

CARRA connects our partners with a robust network of patients and families to gather insights, understand the patient perspective, and engage in focus groups and roundtables to support patient-centered research and drug development.

**Utilizing patients in the research process ensures that the right research questions are asked and improves study participation.**

**I'm really proud that CARRA has led the way in pediatric rheumatology research, while making sure that patients are involved in every aspect of the research that we do.**

**YUKIKO KIMURA, M.D.**
**CARRA Co-Founder and Past President**
On The CARRA Podcast



PARTNERING WITH CARRA

# Registry & Biorepository

CARRA is modernizing the largest pediatric rheumatology registry in North America into a fully interoperable real-world evidence platform.

With 70 sites, the Registry and Biorepository provide unmatched longitudinal clinical data and access to more than 20 biosample cohorts for translational research.

This next-generation infrastructure strengthens data quality, expands equitable participation, integrates biospecimens, and accelerates discovery across the full drug development lifecycle from pre-clinical insights to post-marketing surveillance.

> **CARRA's partners can access the Registry for study-specific project requests.**

## Registry

Post-marketing studies
Observational studies
Pharmacovigilance
Comparative effectiveness
Randomized and non-randomized trials
Biomarker and other translational studies

## Biobank

Plasma
Serum
Cells
DNA
RNA

**16,000+**
patients enrolled

**2,200+**
biosamples in the Biobank

CARRA

# Registry data snapshot

1

### Detailed Clinical and Patient-Reported Outcomes

The Registry captures standardized disease activity measures like SLEDAI for lupus and PROs across rheumatic diseases directly from clinicians and patients.

2

### Comprehensive Data Capture

Every record includes standard, comprehensive data collection, including family history, disease onset, medication history, safety events, and lab results.

3

### A Decade of Data Collection

No other registry tracks pediatric rheumatic disease this closely, consistently, or for as long.

In pediatric rheumatology, real-world evidence is the CARRA Registry and Biorepository.

SUPPORTING MEDICAL AFFAIRS

# Questions worth asking


CARRA can help identify the unmet medical needs of children with rheumatic diseases across pediatric populations and look at questions relevant to adult populations, as well.

The CARRA Registry gives your team a direct way to explore these questions and more.

**16,000+ patients are enrolled in the CARRA Registry.**

**CARRA offers access to data that can answer lingering questions and addresses unmet needs in pediatric rheumatology and beyond.**

ADDRESSING ISSUES IN MEDICAL AFFAIRS



CARRA

LIFECYCLE PARTNERSHIP

# Across the full product lifecycle

**20** biosample cohorts

**70** sites nationwide

Engagement with CARRA can add value at each stage of an asset's life.

## Where CARRA adds value, stage by stage

### PRE-APPROVAL: DESIGN & DE-RISK

Disease activity measures, endpoints, current treatment patterns, patient identification, and regulatory engagement.

### APPROVAL: EVIDENCE FOR REGULATORS

Real-world evidence supporting extrapolation pathways and FDA-aligned infrastructure.

### POST-LAUNCH: SURVEILLANCE & EXPANSION

Long-term safety monitoring and real-world effectiveness.

### ONGOING: MEDICAL AFFAIRS & VALUE

Unmet-need identification, off-label use patterns, and outcomes data relevant to Medical Affairs and HEOR conversations.

PARTNERING WITH CARRA

# Workforce development activities

## Pediatric Rheumatology Early Investigators Meeting
### A direct investment in workforce innovation

PREIM is a national forum for innovative ideas and abstract presentations fostering collaboration amongst peers and mentorship with senior faculty.

The meeting encourages academic career pathways in research, quality improvement, and education.

Corporate sponsorship opportunities offer visibility and awareness while engaging researchers, thought leaders, and the future of rheumatology.

## Annual Scientific Meeting
### Convening the pediatric rheumatology community

The ASM brings together the entire pediatric rheumatology community including physicians, scientists, investigators, nurses, research coordinators, fellows and residents, patients, caregivers and other stakeholders to foster collaboration, knowledge-sharing, and innovation.

The ASM offers exhibits, sponsorships, industry panel sessions, workgroup access for partners, and patient and expert engagement opportunities.

2025 - 2026

# The impact of our annual scientific meeting

**~450**
attendees

**11**
countries

**38**
states

**70**
meetings

> **Convening the community and transforming the field.**

PARTNERING WITH CARRA

# CARRA Grants Program

## Research that supports all career levels.

CARRA is the only funding source exclusively focused on the pediatric rheumatology community in North America.

### EXAMPLE AWARD AREAS

- Lupus
- JIA
- Scleroderma
- JDM and JPM
- Vasculitis
- CRMO/CNO
- APS



**255**

**grants awarded since 2016**

SINCE 2016

# The impact of our grants

**255**

**grants awarded**

to 145 unique primary investigators.

**$12.5M+**

**awarded in total**

across all award levels.

**125+**

**publications**

resulting from funded work.

**$15M**

**in add-on funding**

secured beyond the original grants.

> **Every grant application is reviewed by a patient and/or caregiver.**

CORPORATE PARTNER PROGRAM

# Annual benefits & recognitions



CARRA

CORPORATE PARTNER PROGRAM

# What we offer, at a glance

**5** partnership tiers

**4** benefit categories

Every Corporate Partner Program tier is designed to meet our partners where they are and scaled to fit optimum levels of engagement.

## Corporate Partner Program Benefits

### DRUG DEVELOPMENT & REGULATORY

Strategic input on regulatory taskforces, FDA-aligned initiative access, and biannual reporting on drug development progress.

### REGISTRY, TRIALS & INVESTIGATORS

Custom Registry & Biorepository data reports, clinical trial recruitment promotion, and direct connections to investigators in your priority areas.

### STRATEGIC & COMMUNITY ENGAGEMENT

Executive leadership and subject matter expert meetings, Corporate Advisory Council membership, workgroup and committee leader access, and roundtable and focus group opportunities with scientists, physicians, patients, and families.

### VISIBILITY, AWARENESS & RECOGNITION

Press releases, annual report placement, social and digital media recognition, newsletter features, and visibility and presence at CARRA's Annual Scientific Meeting and PREIM.

PARTNERSHIP TIERS

# Presenting



## ACCELERATING DRUG DEVELOPMENT

Lead Partner · Strategic input during regulatory taskforce meetings · Biannual report

## CLINICAL TRIAL RECRUITMENT

Promotion of clinical trial opportunities · Recruitment opportunities across CARRA's network sites (3)

## INVESTIGATOR-SPONSORED TRIALS

Connect with investigators in areas of mutual interest (3)

## STRATEGIC LEADERSHIP ENGAGEMENT

One private meeting with CEO and Executive Committee (60 minutes) · Five subject matter expert meetings (30 minutes, 1–2 experts) · Corporate Advisory Council membership with co-host opportunity

## PUBLIC RELATIONS & COMMUNICATIONS

Press release with quote · Impact feature report with quote · Annual report premier logo placement

## DIGITAL & SOCIAL MEDIA

Campaign recognition (3 mentions) · Social media recognition (4 mentions) · Cross-promotion of corporate, disease-specific, or educational offerings (3) · Premier website recognition · Digital badge

PARTNERSHIP TIERS · CONTINUED

# Presenting



## NEWSLETTER

Feature story (2) · Individual partner recognition (3 mentions) · Cross-promotion of corporate, disease-specific, or educational offerings (3)

## REGISTRY & BIOREPOSITORY

“First Look” Annual Report · Custom data report (6 reports with up to 2 revisions)

## PHYSICIAN & COMMUNITY

Committee leader engagement (4) · One annual Physician Roundtable (45 minutes, 4–5 pediatric rheumatologists)

## PATIENTS & FAMILIES

Three focus groups (30 minutes, 2 patients) · One annual Patient/Family Roundtable (45 minutes, 4–5 patients/family members)

## EVENT: ASM

Podium remarks · Workgroup engagement · Logo · Exhibit booth and 2 badges · Recognition · Travel support recognition · Banner sponsorship discount

## EVENT: PREIM · RESEARCH AWARD

Recognition on signage and materials · Corporate recognition for supporting award of choice

PARTNERSHIP TIERS

# Visionary



## ACCELERATING DRUG DEVELOPMENT

Strategic input · Biannual report

## CLINICAL TRIAL RECRUITMENT

Promotion of clinical trial opportunities (2)

## INVESTIGATOR-SPONSORED TRIALS

Connect with investigators in areas of mutual interest (2)

## STRATEGIC LEADERSHIP ENGAGEMENT

Four subject matter expert meetings (30 minutes, 1–2 experts) · Corporate Advisory Council membership

## PUBLIC RELATIONS & COMMUNICATIONS

Press release with quote · Impact feature report · Annual report preferred logo placement

## DIGITAL & SOCIAL MEDIA

Campaign recognition (2 mentions) · Social media recognition (3 mentions) · Cross-promotion of corporate, disease-specific, or educational offerings (2) · Preferred website recognition · Digital badge

PARTNERSHIP TIERS · CONTINUED

# Visionary



## NEWSLETTER

Feature story (1) Individual partner recognition (2 mentions) · Cross-promotion of corporate, disease-specific, or educational offerings (2)

## REGISTRY & BIOREPOSITORY

Annual report · Custom data report (4 reports with up to 2 revisions)

## PHYSICIAN & COMMUNITY

Committee leader engagement (3) · One annual physician roundtable (45 minutes, 4–5 pediatric rheumatologists)

## PATIENTS & FAMILIES

Two focus groups (30 minutes, 2 patients) · One annual patient/family roundtable (45 minutes, 4–5 patients/family members)

## EVENT — ASM

Workgroup engagement · Logo · Exhibit booth and 2 badges · Recognition · Travel support recognition · Banner sponsorship discount

## EVENT — PREIM · RESEARCH AWARD

Corporate partner recognition on signage and materials · Corporate recognition for supporting award of choice

PARTNERSHIP TIERS

# Champion

## CLINICAL TRIAL RECRUITMENT

Promotion of clinical trial opportunities (1)

## INVESTIGATOR-SPONSORED TRIALS

Connect with investigator in area of mutual interest (1)

## STRATEGIC LEADERSHIP ENGAGEMENT

Three subject matter expert meetings (30 minutes, 1–2 experts) · Corporate Advisory Council membership

## PUBLIC RELATIONS & COMMUNICATIONS

Press release · Annual report priority logo placement

## DIGITAL & SOCIAL MEDIA

Campaign recognition (1 mention) · Social media recognition (2 mentions) · Cross-promotion of corporate, disease-specific, or educational offerings (1) · Priority website recognition · Digital badge

## NEWSLETTER

Individual partner recognition (1 mention) · Cross-promotion of corporate, disease-specific, or educational offerings (1)

## REGISTRY & BIOREPOSITORY

Annual report · Custom data report (2 reports with up to 2 revisions)

## PHYSICIAN & COMMUNITY · PATIENTS & FAMILIES

Committee leader engagement (2) · One focus group (30 minutes, 2 patients)

## EVENTS: ASM · PREIM

ASM: Workgroup engagement · Logo · Exhibit booth · Banner sponsorship discount
PREIM: Corporate partner recognition on signage and materials

PARTNERSHIP TIERS

# Collaborator

## STRATEGIC LEADERSHIP ENGAGEMENT

Two subject matter expert meetings (30 minutes, 1–2 experts) · Corporate Advisory Council membership

## PUBLIC RELATIONS · DIGITAL & SOCIAL MEDIA

Annual report logo placement · Social media recognition (1 mention) · Cross-promotion of corporate, disease-specific, or educational offerings (1) · Website logo recognition · Digital badge

## NEWSLETTER · REGISTRY · COMMUNITY · EVENTS

Individual partner recognition (1 mention) · Cross-promotion of corporate, disease-specific, or educational offerings (1) · Annual Report · Custom data report (1 report with up to 2 revisions) · Committee leader engagement (1)

ASM: Corporate partner recognition · Workgroup engagement · Logo · Exhibit booth

PREIM: Corporate partner recognition on signage and materials

# Supporter

## STRATEGIC LEADERSHIP ENGAGEMENT

Corporate Advisory Council membership

## PUBLIC RELATIONS · DIGITAL & SOCIAL MEDIA

Annual report recognition · Website logo recognition · Digital badge

## NEWSLETTER · EVENTS

Corporate Partner recognition

ASM: Corporate Partner recognition

PREIM: Corporate Partner recognition

> **Supporter-level partners and above can access the Registry for study-specific project requests.**

NEXT STEPS

# The opportunity



CARRA

Corporate Partner Program

# Together, we can drive transformational change in key segments of pediatric rheumatology for efficient, targeted therapies resulting in life-changing outcomes for kids.

### Accelerating treatment options

De-risking clinical trials through innovative approaches to extrapolation, clinical trial design, partnership with the FDA, and engagement with the EMA.

### Innovation and new science

Ongoing research in immune-mediated diseases and treatment pathways to change the course of disease in children.

### Improving standards of care

Enabling earlier, more effective interventions, helping children achieve better outcomes, and improving quality of life.

### Supporting a critical ecosystem

Investing in the next generation of pediatric rheumatologists, collaborating and engaging with patients and families, and accelerating the drug development process.

**CARRA advocates for patient and caregiver involvement in day-to-day treatment, in research, in workgroups, and the Strategic Planning process. The community knows what they need if you ask them.**

**SHILOH K.** Parent to a child with systemic sclerosis; member of the Strategic Planning Taskforce

CARRA
Childhood Arthritis and Rheumatology Research Alliance

# Thank you!

Contact:
Amy Beith
Corporate Partnerships Director
Email: abeith@carragroup.org
Phone: (404) 323-4487